Company
Alchemi combines cutting-edge AI with deep scientific expertise to help life sciences teams bring therapies to market faster, safer, and more efficiently.
Our Mission
It takes over a decade and more than $2 billion to bring a new drug to market. We founded Alchemi to change this.
We're creating a future where AI will work in tandem with scientists, accelerating drug development. In doing so we can reduce timelines, lower drug costs, and increase access to life saving medicines.
Leadership
Tom Mulvey
Former life science investor at Vitruvian Partners, focused on partnering with CROs and CDMOs. Operating experience at CAR-T manufacturing pioneer Ori Biotech and gene therapy developer Lexeo Therapeutics. MBA from Harvard Business School.
Anuj Chadha
Former senior software engineer at Vecna Robotics, researcher at NASA's Jet Propulsion Lab. Focused on Robotics + Al at Caltech. Experience at Blueyard Capital. MBA from Harvard Business School.
Caroline Atyeo, PhD
Former Staff Fellow of AI at the FDA. Research experience with Moderna as a Senior Scientist focused on infectious disease. PhD in Virology from Harvard Medical School.
Advisory Board
Ben Cons, PhD
Advisor
Former EVP at IQVIA, Former Chair of Castor (ML platform for Clinical Trials), Special Partner at Vitruvian Partners. PhD in Pharmacology.
Mark E. Arnold, PhD
Advisor
Former Director of Science at Labcorp, Former Exec Director at Bristol Myers Squibb, Former Chair of AAPS Scientific Advisory Committee. PhD in Pharmacology.
Nikhil Benesch
Advisor
CTO at Turbopuffer, Former CTO at Materialize, Founding Enginer at Whoop, Founding Engineer at Cockroach Labs.